Ignite Creation Date:
2024-05-06 @ 2:09 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04220476
Status:
WITHDRAWN
Last Update Posted:
2020-09-21
First Post:
2020-01-03
Brief Title:
CIMER Combined Immunotherapies in Metastatic ER Breast Cancer
Sponsor:
Weill Medical College of Cornell University
Organization:
Weill Medical College of Cornell University
Study Overview
Official Title:
CIMER Combined Immunotherapies in Metastatic ER Breast Cancer
Status:
WITHDRAWN
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Initiating a new study with revised Statistics
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CIMER
Brief Summary:
Women with Hormone Receptor HR Human Epidermal growth factor Receptor HER2- metastatic breast cancer are eligible to a randomized trial Patients receiving standard first line therapy for metastatic HR Breast cancerBC letrozolepalbociclib are randomly assigned to also receive Stereotactic Body Radiation TherapySBRT to each metastatic lesion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None